MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Home・Aandelen Lijst・Fate Therapeutics Inc

Fate Therapeutics Inc

Gesloten

SectorGezondheidszorg

1.27 7.63

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.18

Max

1.28

Belangrijke statistieken
By Trading Economics
Inkomsten	-124K -32M
Verkoop	-372K 1.4M
EPS	-0.27
Winstmarge	-2,364.792
Werknemers	161
EBITDA	-13M -42M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+69.49% upside

Dividenden
By Dow Jones
Volgende Winsten	11 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-36M 138M
Vorige openingsprijs	-6.36
Vorige sluitingsprijs	1.27

Nieuwssentiment

By Acuity

50%

161 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

0.9101 / 1.14 Steun & Weerstand

Fate Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9 apr 2026, 23:44 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9 apr 2026, 23:34 UTC

Marktinformatie

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9 apr 2026, 23:14 UTC

Marktinformatie

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9 apr 2026, 23:14 UTC

Marktinformatie

Global Equities Roundup: Market Talk

9 apr 2026, 23:07 UTC

Marktinformatie

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9 apr 2026, 22:54 UTC

Marktinformatie

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9 apr 2026, 22:31 UTC

Belangrijke Nieuwsgebeurtenissen

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9 apr 2026, 22:31 UTC

Belangrijke Nieuwsgebeurtenissen

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9 apr 2026, 20:57 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9 apr 2026, 20:55 UTC

Winsten

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 apr 2026, 20:55 UTC

Winsten

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 apr 2026, 20:55 UTC

Winsten

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9 apr 2026, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

9 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 apr 2026, 20:40 UTC

Acquisities, Fusies, Overnames

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9 apr 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9 apr 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Rowan Digital Infrastructure Announces Strategic Recapitalization

9 apr 2026, 20:25 UTC

Acquisities, Fusies, Overnames

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 apr 2026, 19:30 UTC

Belangrijke Nieuwsgebeurtenissen

How Digital Currencies Have Helped Iran -- WSJ

Peer Vergelijking

Prijswijziging

Fate Therapeutics Inc Prognose

Koersdoel

By TipRanks

69.49% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2 USD 69.49%

Hoogste 2 USD

Laagste 2 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fate Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Fate Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.9101 / 1.14Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

161 / 348 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.